Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

179.33 +1.53 (+0.86%)
Streaming Delayed Price Updated: 10:51 AM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Build Stability and Income With 3 Overlooked Dividend Leaders
Three dividend-paying stocks with high yields present an opportunity for significant passive income but a potentially high dividend payout ratio. 
Via MarketBeat
10 Magnificent S&P 500 Dividend Stocks Down Over 10% to Buy and Hold Forever
These S&P 500 dividend stocks have fallen by up to 33% and are best buys now. 
Via The Motley Fool
Topics Stocks
The Smartest Dividend Stock to Buy With $1,000 Right Now
Via The Motley Fool
Wall Street Sets New Records As Magnificent Seven Valuation Tops $18.5 Trillion: This Week In Markets
Wall Street rose to new heights during the week amid strong earnings and solid economic data. Meanwhile, Fed rate cut debate heats up. 
Via Benzinga
Topics Economy
Deal Dispatch: Del Taco Tanks, Tylenol Maker Aches For Change, Joyebells Burns The Pie
This week's M&A news includes strategic pivots and stumbles galore, with updates from WK Kellogg, Matador Restaurant and Windsurf. 
Via Benzinga
Stock Of The Day: Breakout In Johnson & Johnson
Shares of Johnson & Johnson broke out of a classic ascending triangle pattern. They have since stalled out at resistance. 
Via Benzinga
Want Steady Income? 3 Top Dividend Stocks for July 2025
Three dividend stocks stand out in July, offering reliable income, attractive yields, and strong fundamentals to help investors navigate market volatility 
Via MarketBeat
Topics Economy Lawsuit World Trade
Johnson & Johnson Ups Forecast, Beats On EPS—But Wall Street Is Cautious
Johnson & Johnson earnings came in 3% higher than consensus. The company's operating leverage was "slightly diluted by higher tax." 
Via Benzinga
Johnson & Johnson Analysts Raise Their Forecasts After Upbeat Earnings
 
Via Benzinga
Johnson & Johnson, Intercontinental Exchange And Bitcoin ETF On CNBC's 'Final Trades'
Investors monitor shifting market dynamics and consumer behavior post-pandemic, with Sarat Sethi sticking with Johnson & Johnson amid a positive earnings report. Stephen Weiss picks iShares Bitcoin... 
Via Benzinga
Topics ETFs
Johnson & Johnson's Healthy 3.3%-Yielding Dividend Is a Very Safe Way to Make Passive Income
Via The Motley Fool
Topics Bonds
Is Johnson & Johnson a Good Dividend Stock to Buy Now?
Via The Motley Fool
Johnson & Johnson Credits Tariff Delays For Strong Earnings, While Jim Cramer Pegs It On 'Lower Than Thought' Levies
Johnson & Johnson hinted at leveraging tariff delays to maintain its outlook; however, Jim Cramer credited the performance to lower tariffs. 
Via Benzinga
Topics World Trade
Market Monitor News July 17 BMO (Johnson & Johnson, Brighthouse Financial UP - GrabAGun DOWN)
Powell Panic, Pharma Power & a PEW Parade: Wall Street’s Wild Wednesday 
Via Chartmill
Wall Street Cheers J&J’s Outlook: Morgan Stanley, Stifel Raise Targets After Q2 Beat and Guidance Lift
Analysts highlighted momentum in oncology and MedTech, with Wells Fargo calling the second-half growth acceleration “achievable” and Morgan Stanley noting visibility risks from drug pricing and tariff... 
Via Stocktwits
Topics Government World Trade
Rigetti Computing, Netflix, Johnson & Johnson, United Airlines And ASML: Why These 5 Stocks Are On Investors' Radars Today
U.S. stocks moved higher today, with the Dow Jones gaining more than 200 points, or 0.5%, to close at 44,254.78. 
Via Benzinga
Topics Stocks
3 Top Dividend Stocks Yielding More Than 3% That You Shouldn't Hesitate to Buy Right Now
Via The Motley Fool
JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now
Johnson & Johnson is back in rally mode after years of post-pandemic normalization and the impact of repositioning, set up to sustain higher prices for years. 
Via MarketBeat
Johnson & Johnson Lifts 2025 Outlook
Via The Motley Fool
Topics Intellectual Property
Why Johnson & Johnson Rallied Today
Via The Motley Fool
Topics World Trade
Johnson & Johnson Tops Q2 Estimates
Via The Motley Fool
Topics Intellectual Property
Gold, Bitcoin Surge As Trump Eyes Powell Ouster: What's Moving Markets Wednesday?
Volatility surged across interest rate-sensitive assets Wednesday after reports circulated that President Donald Trump may be preparing to remove Federal Reserve Chair Jerome Powell from his post. The... 
Via Benzinga
Topics Economy Government
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Johnson & Johnson Raises FY25 Forecast, Joins Rigetti Computing, Unity Software, Brighthouse Financial And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
What's going on in today's session: S&P500 movers
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Dow Health Giant J&J Surges After Hiking Outlook On Strong Quarterly Report
The company also easily beat second-quarter adjusted earnings and sales forecasts. 
Via Investor's Business Daily
Topics Stocks
Johnson & Johnson Lifts Annual Forecast After Strong Cancer Drugs, Medtech Performance
Johnson & Johnson beat Q2 estimates and raised its 2025 outlook, driven by strong cancer and MedTech sales despite Stelara declines. 
Via Benzinga
Johnson & Johnson (NYSE:JNJ) Reports Bullish Q2, Full-Year Sales Guidance is Optimistic
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 5.8% year on year to $23.74 billion. The company’s full-year revenue... 
Via StockStory
Johnson & Johnson Outperforms Q2 Expectations; Provides Positive Outlook
Johnson & Johnson surpassed expectations in Q2 2025 with a notable increase in earnings per share and revenue. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.